Streetbeat News

Revenues

CSSE

Chicken Soup for the Soul Entertainment Inc (NASDAQ:CSSE) is exploring financial options to address its cash crisis, including issuing preferred equity, raising new debt, and selling assets. The company, which expanded from publishing to various entertainment sectors, faces financial instability with $4.1 million in cash and $360 million in debt from its merger with Redbox. Despite efforts to reduce costs and renegotiate contracts, its stock has lost over 95% of its value in the past year.

Portfolio Pulse from Anusuya Lahiri

March 06, 2024 | 2:21 pm

BTCUSD

ETHUSD

SPY

Cryptocurrencies including Bitcoin, Ethereum, and Dogecoin face a downturn with $1.15B in potential liquidations. Veteran traders predict a surprise rally for Bitcoin, while Shiba Inu's developer disputes a misquote. Dogecoin's support from Elon Musk keeps it in the spotlight. Ethereum's co-founder sells $100K of ETH amid a dip. US markets show mixed signals with the Fear & Greed Index entering 'Greed' zone and Dow dropping. Nikki Haley's withdrawal from the 2024 Presidential race could favor Trump. US and global politics, economy updates, and tech and EV sector movements, including Tesla's strategies and Rivian's efficiency improvements, are highlighted.

Portfolio Pulse from Akanksha Bakshi

March 06, 2024 | 2:17 pm

ABT

Abbott announced results from two real-world studies indicating that individuals with Type 2 diabetes experienced improvements in their HbA1C levels after incorporating FreeStyle Libre technology into their regimen alongside GLP-1 medicines. This suggests a positive impact of FreeStyle Libre on diabetes management.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:03 pm

DG

Ten analysts have recently reviewed Dollar General (NYSE:DG), offering a mix of ratings from bullish to bearish. The consensus over the last three months shows a predominance of indifferent stances, with no changes in the past 30 days. Analysts have adjusted their price targets, with the average 12-month target now at $131.4, marking an 11.36% increase from the previous average of $118. Analysts from firms like JP Morgan, Morgan Stanley, and Barclays have raised their price targets, reflecting a cautiously optimistic outlook on Dollar General's financial performance, despite its lower market capitalization and challenges in debt management, revenue growth, and asset utilization.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 2:01 pm

ELV

Elevance Health (NYSE:ELV) received 6 somewhat bullish ratings from analysts over the last three months, with an updated average 12-month price target of $563.17, marking a 0.66% increase from the previous target. The company, a leading U.S. health insurer and the largest provider of Blue Cross Blue Shield branded coverage, reported a revenue growth of 6.81% as of December 31, 2023, and outperformed industry averages in net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 2:00 pm

HUM

Humana (NYSE:HUM) has been analyzed by 16 analysts, showing a shift towards a more cautious stance with a significant number of ratings moving to 'Indifferent' in the last 30 days. The average 12-month price target has been adjusted to $461.5, down from $547.09, reflecting a 15.64% decline. Analysts from firms like Barclays, Wells Fargo, and Goldman Sachs have adjusted their price targets and ratings, indicating a varied outlook on Humana's financial health and market performance. Despite positive revenue growth of 17.93% as of December 31, 2023, concerns about Humana's market capitalization, net margin, ROE, ROA, and debt management persist.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 2:00 pm

YMAB

Y-mAbs Therapeutics (NASDAQ:YMAB) received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The average 12-month price target was raised to $23.75, marking a 35.71% increase from the previous target of $17.50. Analysts from HC Wainwright & Co., Canaccord Genuity, and BMO Capital have raised their price targets, reflecting optimism about the company's future performance. Despite a -25.71% decline in revenue growth and challenges in top-line earnings, Y-mAbs Therapeutics exhibits strong financial health with impressive net margin, ROE, and ROA, alongside a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 2:00 pm

ALHC

Alignment Healthcare (NASDAQ:ALHC) has received mixed analyst ratings over the last three months, with a shift towards a more bearish stance in the last 30 days. The average 12-month price target for ALHC has increased to $9.25 from $8.88. Analysts from firms like Barclays, UBS, Stifel, Raymond James, and Stephens & Co. have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Alignment Healthcare, a provider of Medicare Advantage plans, has shown impressive revenue growth of 28.63% as of December 31, 2023, but struggles with profitability and efficient asset utilization, as indicated by its net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 2:00 pm

CJET

Chijet Motor Company, Inc. (NASDAQ:CJET), a Chinese high-tech enterprise, has exported 100 Senia R7 taxis to Colombia through its subsidiary FAW Jilin, marking a significant step in its global expansion. The deal is valued at $785,000. This move into South America reflects Chijet's commitment to entering new markets and its focus on sustainable transportation. The company anticipates increased exports in 2024 and plans further expansion into North Africa, the Middle East, Central Asia, and Oceania.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:38 pm

ATOS

Data from Atossa Therapeutics' Phase 2 EVANGELINE clinical trial will be presented at the American Association for Cancer Research Annual Meeting. This presentation could potentially impact the perception of Atossa's progress in developing treatments for cancer.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:31 pm